Bambusa Therapeutics website screenshot

Bambusa Therapeutics

Bambusa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the Boston Seaport, founded in 2024 by Shanshan Xu and Helmut Jeggle to develop next-generation bispecific antibodies for immunological and inflammatory (I&I) diseases. Its antibody-engineering platform combines half-life extension with high-concentration subcutaneous delivery, and its pipeline spans dermatology, respiratory, gastroenterology and rheumatology — led by BBT-001 (IL-31 x IL-4Ralpha, in a Phase 1b/2a atopic dermatitis trial) and BBT-002 for COPD. The company raised a Series Seed in 2024, an approximately $90M Series A led by RA Capital Management in February 2025, and an oversubscribed Series A-2 in November 2025. It is a therapeutics developer, not a software vendor, and publishes no public API, SDK or developer program.

Bambusa Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.

🌐 Visit website 📡 Source on GitHub
5.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesImmunologyClinical TrialsDrug DevelopmentAntibodies

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 5.1/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Commercial Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 3.9 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/bambusa-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Bambusa Therapeutics Domain Security

TLSv1.3 · DNSSEC · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 2

The organization behind the API

Website
Website
 About
About

Other 1

Properties that don't map to a standard resource type

SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: bambusa-therapeutics
name: Bambusa Therapeutics
description: Bambusa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the Boston Seaport, founded
  in 2024 by Shanshan Xu and Helmut Jeggle to develop next-generation bispecific antibodies for immunological and inflammatory
  (I&I) diseases. Its antibody-engineering platform combines half-life extension with high-concentration subcutaneous delivery,
  and its pipeline spans dermatology, respiratory, gastroenterology and rheumatology — led by BBT-001 (IL-31 x IL-4Ralpha,
  in a Phase 1b/2a atopic dermatitis trial) and BBT-002 for COPD. The company raised a Series Seed in 2024, an approximately
  $90M Series A led by RA Capital Management in February 2025, and an oversubscribed Series A-2 in November 2025. It is a
  therapeutics developer, not a software vendor, and publishes no public API, SDK or developer program.
url: https://raw.githubusercontent.com/api-evangelist/bambusa-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Clinical Trials
- Drug Development
- Antibodies
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/bambusa-therapeutics-domain-security.yml
- type: Website
  url: https://bambusatx.com/
- type: About
  url: https://bambusatx.com/about/
- type: SecondaryMarket
  url: https://forgeglobal.com/bambusa-therapeutics_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Bambusa is a 2024-founded clinical-stage antibody developer whose only web property, bambusatx.com, is a marketing
    site sitting entirely behind a SiteGround captcha (every path, including /, answers 202 with an sgcaptcha redirect), while
    DNS resolves no api./docs./developers./portal. host and no company GitHub organization exists — the product is a bispecific-antibody
    pipeline, not software, so there is no API to publish.
  evidence:
  - url: https://bambusatx.com/openapi.json
    status: 202
  - url: https://bambusatx.com/.well-known/agent-card.json
    status: 202
  - url: https://bambusatx.com/.well-known/security.txt
    status: 202
  - url: https://bambusatx.com/
    status: 202
  checked: '2026-08-06'